Substance · opioid

Opioids (opiates)

The federal panel's opiates assay targets morphine, codeine, and 6-acetylmorphine (a heroin-specific marker). Semi-synthetic opioids like oxycodone and hydrocodone are detected by separate, expanded panels and require additional analytes.

Last updated:

What is Opioids (opiates)?

Opioids are a class of compounds — natural (morphine, codeine), semi-synthetic (oxycodone, hydrocodone), and synthetic (fentanyl, methadone) — that bind to opioid receptors. Standard "opiate" immunoassays primarily detect morphine and codeine; expanded assays add semi-synthetics; fentanyl and norfentanyl became part of the federal panel in 2025.

Panels that include Opioids (opiates)

What drug tests detect

Drug tests for Opioids (opiates) typically target the following analytes / metabolites:

  • Morphine
  • Codeine
  • 6-acetylmorphine (heroin-specific)
  • Hydromorphone
  • Oxymorphone

Confirmation testing uses GC-MS or LC-MS/MS.

Detection windows

Approximate detection windows for Opioids (opiates)
Specimen Window Pattern Caveat
Urine 1–3 days occasional Morphine/codeine typically clear within ~3 days.
3–7 days chronic Detection extends with chronic use, particularly with semi-synthetics.
Saliva 1–48 hours typical Oral fluid window is short; useful for recent use detection.
Blood 1–24 hours typical Plasma half-life is generally short.
Hair 7–90 days typical ~7–10 day incorporation delay; hair is not federally approved.

Ranges are approximate and vary by individual physiology, hydration, dose, frequency of use, and lab cutoff. They are not predictive of whether someone will "pass" a test.

Cross-reactivity and MRO interpretation

The following can affect initial immunoassay screening and are normally resolved by mass-spectrometry confirmation and MRO review. None of these are a reason to draw conclusions from a single screening result.

  • Poppy seeds (ingestion, not cross-reactivity, but causes positive immunoassay)
  • Quinolone antibiotics (rare)
  • Rifampin (rare)

Sources & references

drugtest.co content is sourced from primary regulatory and clinical references. We do not cite gray-market or "how to pass" sources.

  1. Mandatory Guidelines for Federal Workplace Drug Testing Programs (Urine) — SAMHSA
  2. Final Notice — Addition of Fentanyl and Norfentanyl to Federal Workplace Drug Testing Panels — Federal Register / SAMHSA, 2025-02-12
  3. 49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs — U.S. Department of Transportation